Analytical Blind Spots That Derail Microbial Programs Before The Clinic

Inclusion body (IB) expression in E. coli has evolved from a manufacturing challenge into a powerful strategy for producing recombinant proteins at scale. However, success depends on far more than achieving high refolding yields. Demonstrating structural equivalence, confirming biological activity, and controlling product quality require a robust analytical framework integrated throughout development.

Advanced characterization techniques such as CD, FTIR, HDX-MS, native MS, disulfide mapping, and functional assays help establish confidence that refolded proteins meet regulatory and clinical expectations. Equally important, upstream fermentation conditions directly influence IB quality, purity, and downstream refolding performance, making process optimization a critical early step.

By combining analytical rigor with process development from the outset, development teams can reduce scale-up risks, avoid costly rework, and build a stronger path to clinical and commercial manufacturing. Read the full document for deeper insights into modern inclusion body development strategies.